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Structured abstract  
Aims: To describe trends in the incidence of visual impairment and blindness due to diabetic 
retinopathy among adults aged 18-69 years in Ireland between 2004 and 2013.  
 
Methods: Data on visual impairment due to diabetic retinopathy in adults aged 18-69 years or over 
who are registered with the National Council for the Blind of Ireland, (2004-2013) were analysed. 
Annual incidence rates were calculated for the adult population and the population with diagnosed 
diabetes. Poisson regression was used to test for changes in rates over time. The relative, 
attributable and population risk of blindness and visual impairment due to diabetic retinopathy were 
calculated for 2013.  
 
Results: Over the decade, the prevalence of diagnosed diabetes increased from 2.1% to 3.6%. 
Among people with diagnosed diabetes, the incidence of visual impairment due to diabetic 
retinopathy increased from 6.4 (95% CI 2.4-13.9) per 100,000 in 2004 to 11.7 (95% CI 5.9-21.0) per 
100,000 in 2013. The incidence of blindness due to diabetic retinopathy varied from 31.9 per 
100,000 (95% CI 21.6-45.7) in 2004 to 14.9 per 100,000 (95% CI 8.2-25.1) in 2013.  
 
Conclusions: Our findings indicate the need for increased attention to preventive measures for 
microvascular complications among adults with diabetes in Ireland. Retinopathy screening has been 
standardised in Ireland, these findings provide useful baseline statistics to monitor the impact of this 
population-based screening programme. 
Keywords: Diabetes; Diabetic Retinopathy; Trends; Epidemiology; Adults 
 
 
  
3 
 
1. INTRODUCTION 
Vision impairment is a major public health problem worldwide [1]. In 2010, it was estimated that 
0.5% of the global population were blind [1].  In Ireland, the prevalence of blindness increased from 
0.2% in 2003 [2] to 0.3% in 2010 [3]. Worldwide approximately 80% of visual impairment cases can 
be prevented or cured [4]. In order to reduce the global burden of visual impairment, nine 
preventable causes of visual impairment have been prioritised on the global public health agenda 
including diabetic retinopathy [4]. Compared to the general population, individuals with diabetes are 
at an increased risk of losing their eyesight [5]. Genz et al. found that the risk of blindness in an 
individual was 2.4 times that of an individual without diabetes [6].  In Ireland there is no diabetes 
register or national data-capture system to observe diabetes trends in diabetes incidence or 
prevalence over time.  However, findings from a recent systematic review [7] suggest that the 
prevalence of diagnosed diabetes increased from 2.2% in 1998 to 5.2% in 2015. The review was 
unable to distinguish between the various types of diabetes [7]; however it can be assumed that 
type 2 diabetes  is driving the increase in prevalence as it accounts for 90 % of all diabetes cases [8]. 
As the prevalence of diabetes rises, visual impairment due to diabetic retinopathy represents a 
growing global public health challenge [9].  
 
Diabetic retinopathy is a leading cause of preventable vision loss in countries such as the UK [10] and 
the USA [11]. In Ireland, it was the second most common cause of blindness among adults aged 16-
64 years in 2003, with an incidence rate of 0.7 per 100 000 adults [2]. Retinitis pigmentosa was the 
most common cause of blindness among adults aged 16-64 years in 2003; with an incidence rate of 
0.9 per 100 000 adults [2]. The individual and societal costs of visual impairment due to diabetic 
retinopathy are significant [12, 13], and include increased healthcare costs [14, 15], loss of 
productivity [15], and sever reduction in healthy life years [16] and quality of life [17].  
It is now widely accepted that systematic screening for diabetic retinopathy has the potential to 
reduce the incidence of sight-threatening visual impairment [18]. A reduction of rates of blindness 
  
4 
 
due to diabetic retinopathy have been noted in countries that have established population-based 
retinal screening programmes as part of their national diabetes strategy [6, 19-23].Up until recently, 
there was no national population-based screening programme for diabetic retinopathy in Ireland; 
screening was delivered on a limited basis by local services using different models of service 
provision [24]. In 2013, a national retinal screening programme (Diabetic RetinaScreen) was 
introduced in Ireland [25] with the objective of reducing blindness by 40% through the 
implementation of a standardised screening and treatment service [26]. The service was introduced 
on a phased basis, patient registration began in 2013 and full implementation was achieved in late 
2014.  
 
In 2010, the World Health Organisation highlighted the importance of within-country data on visual 
impairment to facilitate global efforts aimed at monitoring and eliminating avoidable blindness [4]. 
Given that the national programme has only been recently introduced, there is limited national data 
on rates of visual impairment due to diabetic retinopathy in Ireland [7]. Therefore, this study used 
national blind registry data to establish current rates of visual impairment and blindness due to 
diabetic retinopathy. Data from blind registers allow the absolute burden of visual impairment 
attributed to diabetic retinopathy to be quantified [27]. In Ireland, blind registry data have been 
previously used to describe trends in all-causes of blindness in 1996 [28] and 2003 [2]. The aims of 
this study were to 1) estimate the incidence of visual impairment and blindness due to diabetic 
retinopathy among (a) the total adult population and (b) population with diagnosed diabetes in 
Ireland over a ten year period (2004-2013); 2) explore whether these rates have changed over time 
and 3) estimate the relative, attributable and population attributable risk of visual impairment and 
blindness due to diabetic retinopathy in Ireland in 2013.  
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2. SUBJECTS MATERIALS AND METHODS 
2.1 Data source 
Data from the National Council for the Blind of Ireland (NCBI) were analysed. The NCBI is a charitable 
organisation which provides support and services to people experiencing sight loss [29]. Anyone who 
is having significant difficulty with their eyesight can be referred to the NCBI by a health care 
professional or family member; self-referral is also possible [29]. Once referred, the individual’s 
information is added to the NCBI database; however, an ophthalmic assessment report (OAR), to 
confirm the level of visual impairment, is necessary to officially register with the service [29]. 
Registration with the NCBI is not compulsory, however those who register can access a range of 
NCBI support services and registration is also required to qualify for the state-provided Blind Welfare 
Allowance [30]. The NCBI registry comprises data on approximately 15 causes of visual impairment 
and blindness, including macular degeneration, glaucoma, cataract, optic atrophy, retinitis 
pigmentosa and diabetic retinopathy [2, 3]. Information such as service-user demographics (gender 
and date of birth), date of registration, visual acuity score and cause of visual impairment are 
recorded on a centralised national database. Information on type of diabetes, the stage of diabetic 
retinopathy, or risk factors for diabetic retinopathy is not recorded. In this study, anonymised data 
on visual impairment due to diabetic retinopathy in adults aged 18-69 years, (January 2004-
December 2013) were obtained for analysis. 
2.2 Numerator data 
The number of new cases of visual impairment due to diabetic retinopathy was extracted from the 
NCBI database for each calendar year. The number of new cases due to all other causes of visual 
impairment was extracted for 2013. Cases were excluded if visual acuity score was not recorded. In 
Ireland, visual impairment is categorised into three levels: mild visual impairment (visual acuity 
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between 6/12 and 6/18 inclusive), moderate visual impairment (best-corrected acuity of less than 
6/18 but better than or equal to 6/60 in the better-seeing eye) and blindness (visual acuity of 6/60 
or less in the better eye or a visual field restricted to 20 degrees or less) [31]. These criteria are 
commonly used in North America, Australia, and most of Europe [31]. For the purpose of this study, 
individuals who met the national criteria for mild and moderate visual impairment were defined as 
‘visually impairment’ and those who met the criteria for blindness were defined as ‘blind’.  
2.3 Denominator data 
Annual population estimates were obtained from the Central Statistics Office (CSO), Ireland [32]. A 
census took place in Ireland in 2006 and 2011; data for other study years were CSO inter-censal 
estimates [32]. A diabetes register does not exist in Ireland, therefore rates for diagnosed diabetes 
was taken from model estimates; methods have been described in detail previously [7]. In brief, 
using data from four nationally representative population-based studies , multivariate Poisson 
regression models were undertaken to impute annual gender and age-specific (18–29 years, 30-39 
years, 40-49 years, 50-59 years, 60-69 years) rates of diagnosed diabetes. These gender and age-
specific rates were applied to 2004–2013 population data so the absolute number of diabetes cases 
could be obtained. For the purpose of this study, the absolute number of diabetes cases was 
categorised into two age groups (18-49 years, 50-69 years). The population without diagnosed 
diabetes was calculated by subtracting the estimated population with diabetes in 2013 from the 
total population in 2013.  
 
2.4 Incidence calculations 
The incidence of visual impairment and blindness due to diabetic retinopathy in the total population 
and the population with diagnosed diabetes was calculated for each year 2004–2013; using data 
from the NCBI as the numerator and the census and estimated diabetes population as the 
denominator for the total population and diagnosed diabetes populations respectively. The 
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incidence of visual impairment and blindness due to all other causes in the population without 
diagnosed diabetes was calculated for 2013; using data from the NCBI as the numerator and the 
estimated population without diabetes as the denominator. Rates were expressed per 100, 000 
population.  
2.5 Statistical analysis 
Age-standardised rates in the total population and the population at risk (in 10-year age groups) 
were calculated using the direct standardisation method, based on the age distribution of the last 
census in Ireland (2011) and the estimated population with diagnosed diabetes in 2011, respectively; 
95% confidence intervals (95% CI) were based on the Poisson distribution. Mean incidence figures, 
with standard deviations (SD) and 95% CI’s, were calculated for the decade. The risk of visual 
impairment increases with age [33]; therefore analysis was stratified by two arbitrary age groups 
(18-49 years, 50-69 years). Poisson regression models, using extra Poisson variation, were 
undertaken to explore variations in rates overtime and to examine departures from linearity 
between 2004 and 2013. Sensitivity analysis, comparing rates in the total population between 
census year (2006 and 2011) was also carried out.  The number of cases served as the dependant 
variable, year of registration served as the continuous independent variable and population was 
entered as the exposure variable. If this model indicated significant changes in the IRR over time 
(pchange), the likelihood ratio test was undertaken to assess linearity. A model including year of 
registration as a categorical variable was compared to the model with year as registration as a 
continuous variable.  Linearity was determined by an insignificant likelihood ratio test (ptrend). The 
IRR with corresponding 95% CI were reported if linearity was established. A two-sided p<0.05 was 
considered statistically significant. 
Age-specific relative risks of blindness and visual impairment (diabetes vs. no diabetes) in 2013 were 
calculated by dividing the rates in the estimated population with diabetes by the rates in the 
population without diabetes. The attributable risk (AR) [incidence exposed –incidence unexposed], 
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attributable risk percent (AR %) [AR/ incidence exposed *100], population attributable risk (PAR) 
[incidence population –incidence unexposed] and the population attributable risk percent (PAR %) [PAR/ 
incidence population * 100] were also calculated. The AR measures the excess risk attributed to 
diabetes, using the difference between the risk in individuals with diagnosed diabetes (exposed) and 
that in individuals without diabetes (unexposed). The PAR measures the excess risk between the risk 
in the total population in the total population and that in individuals without diagnosed diabetes 
(unexposed). Analysis was carried out in Stata 13. 
3. RESULTS 
A total of 357 new cases of diabetic retinopathy were registered with the NCBI during the 10 year 
period; 16 cases (5%) were excluded as an OAR had not been returned to the NCBI, therefore the 
level of visual impairment could not be determined. The distribution of these cases over the study 
period is shown in supplementary file 1. Therefore, 341 new cases were available for inclusion in the 
current analysis. Between 2004 and 2013, a total of 86 cases were newly registered as visually 
impaired (supplementary file 2); of these 67% were male and the median age was 62 years (IQR 57-
66). The highest proportion of new cases of visual impairment also occurred in those aged 50-59 
years (50-69 years: 73 vs. 18-49 years: 13). A total of 255 patients were newly registered as blind 
(supplementary file 3); of these, 58% were male and the median age of registration was 59 years 
(IQR 51-65). The highest number of new blind cases occurred in those aged 50-69 years (50-69 years: 
195 vs. 18-49 years: 60).  During 2013, 207 people (87 visually impaired and 120 blind), were newly 
registered on the NCBI database due to all other causes.  
Over the ten year period, the prevalence of diagnosed diabetes increased from 2.1 % (95% CI: 2.0-
2.2) in 2004 to 3.6% (95% CI: 3.5-3.7) in 2013; (ptrend= <0.001). Table 1 shows the number of new 
cases for each year, the total adult population, the estimated adult population with diabetes, the 
standardised incidence of visual impairment and blindness attributed to diabetic retinopathy. 
Between 2004 and 2013, the mean annual incidence of visual impairment due to diabetic 
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retinopathy was 0.3 per 100,000 population (SD: 0.09; 95% CI: 0.2-0.4) and 10.7 per 100,000 
population with diagnosed diabetes (SD: 2.9; 95% CI: 8.6-12.7). During the same time period, the 
mean annual incidence of blindness due to diabetic retinopathy was 0.9 per 100,000 adults (SD: 
0.24; 95% CI: 0.7-1.04) and was 33.2 per 100,000 population with diagnosed diabetes (SD: 10.2; 95% 
CI: 25.9-40.5). Over a decade, the incidence of visual impairment due to diabetic retinopathy 
increased in both the total population (IRR: 1.08 [95% CI: 1.01-1.16]; ptrend=0.93) and the population 
with diagnosed diabetes (IRR: 1.05 [95% CI: 1.02-1.1]; ptrend= 0.79). In contrast, the incidence of 
blindness due to diabetic retinopathy in the total population did not significantly change during the 
study period (pchange= 0.73). Over the 10 year period, the annual incidence in the population with 
diabetes did vary between years (pchange=0.01); however, there was no evidence of a linear trend 
(ptrend <0.01).  
Figure 1b illustrates the age-specific trends of visual impairment between 2004 and 2013. Among 
adults aged 18-49 years, the incidence remained steady in the total population (2004: 0.05 [95% CI 
0.001-0.3] to 2013: 0.04 [95% CI 0.001-0.4] per 100,000; pchange = 0.56), whereas among people with 
diabetes, the incidence ranged from 5.4 (95% CI 0.1-30.0) in 2004 to 2.3 (95% CI 0.05-12.8) per 
100,000 in 2013 but did not significantly change overtime (pchange = 0.83). In contrast, among adults 
aged 50-69 years, the incidence increased in both the total population (2004: 0.3 [95% CI 0.08-1.2] 
to 2013: 1.3 [95% CI 0.6-2.2]; [IRR: 1.09 [1.05-1.13]; ptrend = 0.92) and the population with diabetes 
(2004: 7.6 [95% CI 15.8-22.5] to 2013: 18.1 [95% CI 9.4-31.6]); [IRR: 1.05 [95% CI: 1.02-1.09]; 
ptrend = 0.92).  
Figure 1c illustrates age-specific trends of blindness due to diabetic retinopathy between 2004 and 
2013. Among adults aged 18-49 years, the incidence remained stable in the total population (2004: 
0.2 [95% CI 0.08-0.5] to 2013: 0.2 [95% CI 0.07-0.6] per 100,000; pchange = 0.56). However, among 
people with diabetes, the incidence ranged from 26.9 (95% CI 8.7-62.8) per 100,000 in 2004 to 11.5 
(95% CI 3.7-26.8) per 100,000 in 2013 but did not significantly change overtime (pchange = 0.45). 
Among adults aged 50-69 years, the incidence also remained stable in the total population (2004: 
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1.7 [95% CI 0.9-2.9] to 2013: 1.2 [95% CI 0.5-2.1] per 100,000; pchange = 0.15). Whereas among people 
with diabetes, the incidence varied from 33.3 (95% CI 17.7-56.9) in 2004 to 16.6 (95% CI 8.3-29.7) 
per 100, 000 in 2013 (pchange = 0.03); however, there was no evidence of a linear trend (ptrend <0.01).  
 
Sensitivity analysis: trends in the total population between census years (2006-2011) 
The results from the sensitivity analysis demonstrated that the incidence of visual impairment 
(pchange= 0.31) or blindness (pchange= 0.59) due to diabetic retinopathy in the total population did not 
significantly change between 2006 and 2011. Among adults aged 18-49 years, the incidence of visual 
impairment and blindness remained stable (visual impairment: 2006: 0.05 [95% CI 0.08-0.5] to 2011: 
0.09 [95% CI 0.07-0.6] per 100,000; pchange = 0.98; blindness: 2006: 0.3 [95% CI 0.08-0.5] to 2011: 0.3 
[95% CI 0.07-0.6] per 100,000; pchange = 0.37).  Among adults aged 50-69 years, the incidence of visual 
impairment ranged from 0.6 (95% CI 17.7-56.9) in 2006 to 1.0 (95% CI 8.3-29.7) per 100, 000 in 2011 
but did not significantly change over time (pchange = 0.37). Whereas, the incidence of blindness 
remained stable (2006: 2.6 [95% CI 0.08-0.5] to 2011: 2.4 [95% CI 0.07-0.6] per 100,000; 
pchange = 0.51).  
 
The relative risk, attributable and population attributable risk of blindness and visual impairment in 
2013 are shown in Table 2. In adults aged 18-49 years, the risk of blindness was 5.6 times higher in 
the population with diabetes compared to those without diabetes. In 2013, 9% of the risk of 
blindness in the entire population was attributable to diabetes. In adults aged 50-69 years, the risk 
of visual impairment was 3.9 times higher in the population with diabetes compared to those 
without diabetes. Sixteen per cent of the risk of visual impairment in the entire population was 
attributable to diabetes in 2013. 
 
4. DISCUSSION  
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To our knowledge, this is the first study to describe national rates of registered blindness and visual 
due to diabetic retinopathy among the population with diagnosed diabetes in Ireland. We observed 
a change in the incidence of blindness due to diabetic retinopathy among people with diabetes over 
the study period, however there was insufficient evidence to confirm a downward trend. This is in 
accordance with previous research describing national trends in the incidence of lower leg 
amputations between 2005 and 2009 among the population with diabetes [34]. Findings from the 
present study are in contrast to international research where a decrease in the incidence of 
blindness [6, 10, 20, 22, 23, 35-37] and other diabetes related complications [38] have been 
documented. It has been suggest that while the rates of some diabetes complications have 
decreased, the absolute number of cases will continue to rise because of the rising prevalence of 
diabetes [38]. In the present study, we observed an increase in the prevalence of diagnosed 
diabetes; longer duration of diabetes diagnosis is an established risk factor for diabetic retinopathy 
[9]. After 20 years of diabetes, nearly all individuals with type 1 diabetes and more than two-thirds 
of individuals with type 2 diabetes will develop some degree of retinopathy [12]. Therefore it is 
possible that the full impact of the diabetes epidemic has not yet been realised in Ireland. In 
contrast, an increase in visual impairment was evident in the total population and among people 
with diabetes. 
 
 Comparison with other countries is limited due to differences in visual impairment criteria, differing 
age ranges and varying methods used to estimate the population at risk [8]. In the UK, from 2000 to 
2009, Hall et al. [20] described a decrease in the incidence of blindness attributable diabetes from 
1.43 to 1.10 per 100,000 total population, and 59.7 to 23.9 per 100,000 population with diagnosed 
diabetes. However, unlike the present study, these rates included adults over 70 years rather than 
being restricted to adults aged 18-69 years. Elsewhere in the UK, between 2001 and 2005, the mean 
annual incidence of blindness due to diabetic retinopathy among adults aged 16-64 years with 
diabetes was 22 per 100,000 population [19]. This estimate is lower than our mean annual estimate 
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(22 vs. 33); however the sample in our study was older on average (55 years vs. 59 years) which 
could lead to a higher rate of blindness [33]. In the USA, The Wisconsin Epidemiologic Study of 
Diabetic Retinopathy, reported a decline in the incidence of severe visual impairment over a 25 year 
period among those with type 1 diabetes [39]. 
 
Decreasing trends of blindness and visual impairment due to diabetic retinopathy have been 
attributed to a combination of factors, including improvements in disease management and risk 
factor control, earlier detection and treatment of diabetic retinopathy through the implementation 
of standardised retinopathy screening programmes [21, 40]. In Ireland, data on risk factors for 
diabetic retinopathy are not routinely collated at a population-level, therefore we were unable to 
quantify trends in mean HbA1c levels or mean blood pressure during the study period. Prior to the 
introduction of the national diabetic retinal screening programme, there was wide variation in the 
delivery of diabetic retinopathy screening in Ireland [24]. Regional screening initiatives may have 
contributed to the changing incidence of visual impairment and blindness observed in the present 
study. We found that the incidence of visual impairment due to diabetic retinopathy almost doubled 
over a ten year period; this may be indicative of local efforts to screen for diabetic retinopathy. The 
initial introduction of a screening programme results in the detection of more diabetic retinopathy 
cases [21]. Countries that have introduced population-based retinal screening programmes have 
observed a decline in the frequency [21]and treatment [40] of sight-threatening diabetic retinopathy 
over time. The national Diabetic RetinaScreen programme was fully implemented in 2014; we 
hypothesize that initially, the increasing trend in visual impairment due to diabetic retinopathy will 
continue and will gradually decline post-implementation.  
 
Strengths and limitations 
The strengths of our study include the analysis of a national centralised database that has been 
previously used in Ireland to describe rates of all-causes of blindness in 1996 [28] and 2003 [2]. To 
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our knowledge, rates of blindness due to diabetic retinopathy have not been estimated since 2003. 
Furthermore, the risk of visual impairment attributable to diabetes has not been previously reported 
within the Irish population.  
However, our study has some limitations that must be considered. Firstly, implications of using blind 
registry data to describe rates in visual impairment and blindness have been discussed elsewhere [2, 
20, 41]. It has been suggested that blind registry data may be incomplete, leading to an 
underestimation the true burden of blindness. For example, data from the UK [42] has 
demonstrated that partially sighted individuals are less likely to be registered than blind patients. In 
Ireland, both visually impaired and blind individuals can avail of the services provided by the NCBI 
[29]. However, selection bias due to an underreporting of visual impairment cases maybe possible 
as, unlike blindness, registration to the NCBI is not financially incentivised [30]. Referral to the NCBI 
also may depend on severity of visual impairment further increasing the possibility of self-selection. 
Therefore, in the present study the annual incidence of visual impairment may be underestimated.  
Previous studies have shown that 21-50% [2, 41, 42] of patients are not listed on blind registers; 
furthermore, partially sighted individuals are less likely to be registered than blind patients [42]. 
Non-registration has been associated with temporary and treatable causes of blindness [2, 42]; 
however, blindness due to diabetic retinopathy is irreversible and there is no evidence to suggest 
that under-registration is more likely in those with diabetes. It is also recognised that blind registry 
data is only a surrogate measure of incident blindness [20, 42], where changes in rates may reflect 
reporting differences over time rather than true changes in disease incidence. In the present study, 
it is possible that the NBCI may have become a better known resource over time thereby impacting 
registration to the service. For instance, our findings demonstrated a sharp increase in the number 
of blind cases during 2008, which resulted in a sharp increase in incidence. This increase may be 
attributable to a national campaign specifically highlighting diabetic retinopathy among the general 
population, which in turn may have increased recording rates to the NCBI during this year. 
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Nevertheless, in the absence of any other national data source, blind registries are useful for 
monitoring trends in diabetes-related blindness [27].  
 
Secondly, similar to previous research [19, 34, 43], we applied secondary data to model our annual 
diabetes prevalence estimates. We acknowledge that the accuracy of our calculations is dependent 
on the reliable estimation of the population with diagnosed diabetes. For instance, an 
underestimation of diabetes cases in our denominator would result in an increase in our attributable 
risk calculations. In the absence of a national diabetes register, annual estimates on the prevalence 
of diabetes are lacking [7]. However, our model estimates are derived from four nationally 
representative studies and the increasing prevalence of diagnosed diabetes among the adult 
population in Ireland is in accordance with other countries [7]. Therefore the diabetes prevalence 
estimates used in the present study are the best available in Ireland.  Additionally, in accordance 
with previous research [6, 20, 23, 43], our denominator data does not include those with 
undiagnosed diabetes; we acknowledge that this would result in an overestimation of rates. Finally, 
we could not stratify our analysis by diabetes type and duration of disease was unknown. Our rates 
in the youngest age group serve as a proxy for those with type 1 diabetes, although the small 
number of cases in the youngest age group could introduce imprecision into our estimates.  
 
Despite these limitations our research provides contemporary data on the trends of diabetes related 
complications among adults aged between 18 and 69 years in Ireland [7]. Diabetic retinopathy is 
potentially preventable by adequate risk factor control [12]. Additionally, early detection and timely 
treatment can prevent the onset of sight threatening visual impairment [12, 18] . Our risk 
calculations indicate that in 2013, prevention or early detection of diabetic retinopathy may have 
resulted in 82% fewer new cases of blindness in adults aged 18-49 years and 48% fewer new cases of 
blindness in adults aged 50-69 years. Although causality cannot be inferred in the present study, our 
findings highlight the need to focus on preventive measures for microvascular complications among 
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people with diabetes in Ireland. Evidence suggests that younger adults [44-46] and those with type 1 
diabetes mellitus [44-46] are less likely to attend regular retinal screening examinations; non-
attendance is a risk factor for poor visual outcomes [21]. Therefore, further research is required to 
explore patterns of retinal screening attendance among these groups in Ireland. It is essential to 
develop an understanding of the factors which influence the uptake of the national diabetic retinal 
screening programme in order for this new investment to be effective [47]. Findings from this 
research will provide useful baseline statistics to monitor the future impact of the national diabetic 
retinal screening programme [25].  
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Table 1 New registrations resulting from diabetic retinopathy, estimated population data and the standardised incidence of visual impairment and 
blindness, Ireland 2004-2013.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year      Adult population 
Number of new cases 
due to diabetic 
retinopathy 
Incidence of visual impairment 
due to diabetic retinopathy 
(per 100,000 pop [95 % CI]) 
Incidence of blindness  
due to diabetic retinopathy 
(per 100,000 pop [95 % CI]) 
 
Total 
Diagnosed 
diabetes 
Visual 
impairment 
Blindness Total 
Diagnosed 
diabetes 
Total 
Diagnosed 
diabetes 
2004 2712428 57628 4 18 0.16 (0.05-0.3) 6.4 (2.4-13.9) 0.68 (0.4-1.0) 31.9 (21.6-45.7) 
2005 2789808 61881 6 19 0.23 (0.09-0.4) 9.6 (4.4-18.2) 0.72 (0.5-1.0) 29.9 (19.8-43.2) 
2006 2879284 65829 6 28 0.23 (0.09-0.4) 8.9 (3.9-17.6) 1.01 (0.6-1.4) 42.7 (30.5-58.1) 
2007 2990318 71893 8 25 0.26 (0.1-0.5) 11.7 (5.7-20.9) 0.87 (0.5-1.3) 35.2 (24.2-49.4) 
2008 3061169 77777 9 42 0.29 (0.1-0.5) 10.6 (5.1-19.6) 1.43 (1.0-1.9) 54.4 (40.5-71.5) 
2009 3077885 83627 5 26 0.16 (0.5-0.4) 6.4 (2.3-13.9) 0.87 (0.5-1.3) 33.1 (22.5-46.9) 
2010 3075576 89651 13 27 0.42 (0.2-0.7) 15.9 (8.9-26.4) 0.87 (0.6-1.3) 31.9 (21.6-45.7) 
2011 3077810 96470 11 29 0.35 (0.2-0.6) 12.3 (6.1-22.0) 0.94 (0.6-1.4) 30.9 (20.7-44.4) 
2012 3052159 102775 12 25 0.39 (0.2-0.7) 13.4 (6.9-23.4) 0.81(0.5-1.2) 26.7 (17.3-39.4) 
2013 3032956 109842 13 16 0.39 (0.2-0.7) 11.7 (5.7-21.0) 0.52 (0.3-0.8) 14.9 (8.2-25.1) 
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Table 2 Relative, attributable and population attributable risk of visual impairment 
and blindness due to diabetic retinopathy in Ireland, 2013. 
 
 VI Blindness 
Relative risk (95% CI) 
No diabetes 
18-49 years 
50-69 years 
 
1 
1.7 (0.2-12.3) 
3.9 (2.0-7.4) 
 
1 
5.5 (2.2-13.6) 
1.9 (1.1-3.6) 
AR /100,000 diabetes pop 
18-49 years 
50-69 years 
 
1.0 (-0.03-7.4) 
13.4 (3.1-23.7) 
 
9.4 (0.7-19.4) 
7.8 (2.2-17.8) 
AR % in diabetes pop 
18-49 years 
50-69 years 
 
44.6 (-3.9-94.5) 
74.2 (51.0-86.4) 
 
81.6 (53.7-92.7) 
47.7 (8.4-71.9) 
PAR /100,000 pop 
18-49 years 
50-69 years 
 
0.02 (-2.2-7.3) 
0.9 (0.04-15.2) 
 
0.3 (0.01-10.3) 
0.5 (1.5-13.7) 
PAR % in total pop 
18-49 years 
50-69 years 
 
1.7 (-4.7-18.7) 
16.8 (4.5-28.7) 
 
8.5 (0.3-17.9) 
5.9 (1.8-13.1) 
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Figure 1 Age specific trends in the incidence of A) Any visual impairment; B) Mild and moderate visual impairment  and C) Blindness due to diabetic 
retinopathy among the total adult population and adults with diagnosed diabetes, Ireland 2004-2013.  
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Highlights  
• This is the first study to describe trends in the incidence of visual impairment and 
blindness due to diabetic retinopathy among adults aged 18-69 year in Ireland. 
• Over a decade, the incidence of visual impairment has increased whereas there was no 
evidence of a linear trend in the incidence of blindness. 
• A national retinal screening programme was fully implemented in 2014. These 
findings provide reliable national data to monitor the impact of this population-based 
screening programme. 
 
